About the company
vTv Therapeutics Inc is a renowned clinical stage biopharmaceutical company that is dedicated to advancing the field of diabetes treatment through the development of innovative orally administered therapies. With a strong focus on research and development, vTv Therapeutics is committed to addressing the needs of individuals living with diabetes and improving their quality of life. One of the company's promising lead programs is TTP399. This oral medication is a small molecule liver-selective glucokinase activator (GKA) designed to revolutionize the treatment of type 1 diabetes. TTP399 has the potential to serve as an adjunctive therapy to insulin, providing new options for individuals with this form of diabetes. The liver plays a crucial role in regulating blood glucose levels, and TTP399 seeks to harness the power of glucokinase to enhance glucose metabolism in the liver. By activating glucokinase, TTP399 increases the rate at which the liver converts glucose into glycogen, leading to a reduction in blood glucose levels. This mechanism of action complements the effects of insulin therapy and has the potential to greatly improve glycemic control in individuals with type 1 diabetes. Clinical trials conducted by vTv Therapeutics have shown promising results for TTP399. In a Phase 2 study called Simplici-T1, the medication demonstrated significant and sustained reductions in HbA1c, a key marker of blood glucose control, in individuals with type 1 diabetes. Additionally, TTP399 exhibited a favorable safety profile, with no serious adverse events reported. The potential impact of TTP399 goes beyond controlling blood glucose levels. Effective glucose control is a fundamental aspect of diabetes management, as it helps to prevent the onset of complications associated with the disease. By working alongside insulin therapy, TTP399 may help reduce the reliance on high doses of insulin, potentially minimizing the risk of hypoglycemia, a common side effect of insulin treatment. This could greatly enhance the overall management of type 1 diabetes and improve the quality of life for individuals living with the condition. In addition to its groundbreaking research on TTP399, vTv Therapeutics is committed to exploring other treatment options for diabetes. The company's robust pipeline includes several other potential therapies for type 2 diabetes, such as TTP273, a GKA for individuals with impaired glucose tolerance and type 2 diabetes. Through strategic partnerships and collaborations with leading experts in the field, vTv Therapeutics is at the forefront of diabetes research and development. By harnessing the power of science and innovation, the company aims to bring forth transformative solutions that have the potential to revolutionize diabetes care. In conclusion, vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing innovative orally administered treatments for diabetes. The company's lead program, TTP399, holds tremendous promise as an adjunctive therapy to insulin for individuals with type 1 diabetes. With its continued dedication to scientific research and development, vTv Therapeutics is poised to play a crucial role in advancing diabetes treatment and improving the lives of countless individuals worldwide.
Website: https://vtvtherapeutics.com
Data updated: June 2, 2026
